Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.
Weber M, Niespodziana K, Linhart B, Neubauer A, Huber H, Henning R, Valenta R, Focke-Tejkl M. Weber M, et al. Among authors: huber h. J Allergy Clin Immunol. 2017 Nov;140(5):1433-1436.e6. doi: 10.1016/j.jaci.2017.03.048. Epub 2017 May 31. J Allergy Clin Immunol. 2017. PMID: 28576673 Free PMC article. No abstract available.
Recombinant allergens: what does the future hold?
Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, Niederberger V. Valenta R, et al. Among authors: huber h. J Allergy Clin Immunol. 2011 Apr;127(4):860-4. doi: 10.1016/j.jaci.2011.02.016. J Allergy Clin Immunol. 2011. PMID: 21458656 Review.
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R. Focke-Tejkl M, et al. Among authors: huber h. J Allergy Clin Immunol. 2015 May;135(5):1207-7.e1-11. doi: 10.1016/j.jaci.2014.09.012. Epub 2014 Nov 13. J Allergy Clin Immunol. 2015. PMID: 25441634 Free PMC article.
Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R. Campana R, et al. Among authors: huber h. J Allergy Clin Immunol. 2016 Feb;137(2):601-609.e8. doi: 10.1016/j.jaci.2015.08.042. Epub 2015 Oct 28. J Allergy Clin Immunol. 2016. PMID: 26518092 Free PMC article.
Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R. Zieglmayer P, et al. Among authors: huber h. EBioMedicine. 2016 Sep;11:43-57. doi: 10.1016/j.ebiom.2016.08.022. Epub 2016 Aug 20. EBioMedicine. 2016. PMID: 27650868 Free PMC article. Clinical Trial.
Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.
Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, Quaak S, Akkerdaas JH, Blom L, Asturias J, Bindslev-Jensen C, Bernardi ML, Clausen M, Ferrara R, Hauer M, Heyse J, Kopp S, Kowalski ML, Lewandowska-Polak A, Linhart B, Maderegger B, Maillere B, Mari A, Martinez A, Mills EN, Neubauer A, Nicoletti C, Papadopoulos NG, Portoles A, Ranta-Panula V, Santos-Magadan S, Schnoor HJ, Sigurdardottir ST, Stahl-Skov P, Stavroulakis G, Stegfellner G, Vázquez-Cortés S, Witten M, Stolz F, Poulsen LK, Fernandez-Rivas M, Valenta R, van Ree R. Zuidmeer-Jongejan L, et al. Among authors: huber h. Int Arch Allergy Immunol. 2015;166(1):41-51. doi: 10.1159/000371657. Epub 2015 Feb 28. Int Arch Allergy Immunol. 2015. PMID: 25765512 Free article. Clinical Trial.
Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy.
Lupinek C, Derfler K, Lee S, Prikoszovich T, Movadat O, Wollmann E, Cornelius C, Weber M, Fröschl R, Selb R, Blatt K, Smiljkovic D, Schoder V, Cervenka R, Plaichner T, Stegfellner G, Huber H, Henning R, Kozik-Jaromin J, Perkmann T, Niederberger V, Petkov V, Valent P, Gauly A, Leinenbach HP, Uhlenbusch-Koerwer I, Valenta R. Lupinek C, et al. Among authors: huber h. EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007. Epub 2017 Feb 12. EBioMedicine. 2017. PMID: 28254561 Free PMC article. Clinical Trial.
Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
Kinaciyan T, Nagl B, Faustmann S, Frommlet F, Kopp S, Wolkersdorfer M, Wöhrl S, Bastl K, Huber H, Berger U, Bohle B. Kinaciyan T, et al. Among authors: huber h. J Allergy Clin Immunol. 2018 Mar;141(3):1002-1008. doi: 10.1016/j.jaci.2017.07.036. Epub 2017 Sep 1. J Allergy Clin Immunol. 2018. PMID: 28870463 Clinical Trial.
Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M, Kinaciyan T, Nagl B, Baumgartner-Durchschlag U, Huber H, Ebner C, Lidholm J, Bartel D, Vieths S, Jahn-Schmid B, Bohle B. Geroldinger-Simic M, et al. Among authors: huber h. J Allergy Clin Immunol. 2013 Jan;131(1):94-102. doi: 10.1016/j.jaci.2012.06.039. Epub 2012 Aug 24. J Allergy Clin Immunol. 2013. PMID: 22921871
1,115 results